¼¼°èÀÇ ÈÇй߱¤ ¸é¿ªÃøÁ¤ ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)
Chemiluminescence Immunoassay Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â ¼¼°è ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤(CLIA) ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ º¸°í¼¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ º¸°í¼´Â ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ, °úÁ¦ µî ÁÖ¿ä ½ÃÀå ¿ªÇÐÀ» »ó¼¼ÇÏ°Ô Æò°¡ÇÏ°í ½ÃÀå ±¸Á¶¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
ÈÇй߱¤ ¸é¿ªÃøÁ¤ ½ÃÀå ±Ô¸ð(2024³â) : 950¸¸ ´Þ·¯
½ÃÀå ¿¹Ãø ±Ý¾×(2032³â) : 2,160¸¸ ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2024-2032³â) : 9.5%
ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå - Á¶»ç ¹üÀ§
ÈÇй߱¤ ¸é¿ªÃøÁ¤Àº È£¸£¸ó, ´Ü¹éÁú ¹× ±âŸ ºÐÀÚ¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °ËÃâÇϰí Á¤·®Çϱâ À§ÇÑ Áø´Ü ½ÇÇè½Ç¿¡¼ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®Àº ÈÇÐ ¹ÝÀÀ¿¡ ÀÇÇÑ ¹ß±¤À» ÀÌ¿ëÇÏ¿© ¹Î°¨ÇÏ°í Æ¯ÀÌÀûÀÎ ºÐ¼® °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. CLIA ½ÃÀåÀº º´¿ø, Áø´Ü ½ÇÇè½Ç, ¿¬±¸ ±â°ü, Á¦¾à ȸ»ç¸¦ À§ÇØ ½Ã¾à, Àåºñ, ¼Ò¸ðǰ µî ´Ù¾çÇÑ Á¦Ç°À» Á¦°øÇÕ´Ï´Ù.
½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀº ¸¸¼º Áúȯ Áõ°¡, ºÐ¼® ±â¼úÀÇ Áøº¸, Á¤È®ÇÑ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. CLIA ±â¼úÀÇ Ã¤¿ëÀº ÃÖ¼ÒÇÑÀÇ »ùÇà ¾çÀ¸·Î ³ôÀº 󸮷® °á°ú¸¦ Á¦°øÇÏ´Â ´É·Â¿¡ ÀÇÇØ ´õ¿í Çâ»óµÇ¾î ÃֽŠÁø´Ü¿¡ ÇʼöÀûÀÎ ¿ä¼Ò°¡ µÇ¾ú½À´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ:
ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ¼¼°è ½ÃÀåÀº ¸¸¼º Áúȯ ¹× °¨¿°ÀÇ ÀÌȯÀ² Áõ°¡, Á¶±â ¹ß°ß ¹× °ü¸®¸¦ À§ÇÑ °í±Þ Áø´Ü ¹æ¹ýÀÇ Çʿ伺 µî ¸î °¡Áö Áß¿äÇÑ ¿äÀε鿡 ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·áÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí È¿À²ÀûÀÌ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀå È®´ë¸¦ ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. °í°¨µµ¡¤°í󸮷® CLIA ½Ã½ºÅÛÀÇ °³¹ß µî ±â¼úÀÇ Áøº¸°¡ Áø´Ü ´É·ÂÀ» ³ô¿© ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ½ÅÈï ½ÃÀå¿¡¼ÀÇ Áø´Ü½Ç°ú ÀÇ·á½Ã¼³ÀÇ È®´ë´Â CLIA Á¦°ø¾÷ü¿¡°Ô »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ:
À¯¸ÁÇÑ ¼ºÀåÀÌ ¿¹»óµÇÁö¸¸, ÈÇй߱¤ ¸é¿ªÃøÁ¤ ½ÃÀåÀº CLIA ½Ã½ºÅÛ ¹× ½Ã¾à°ú °ü·ÃµÈ °íºñ¿ë ¹®Á¦¿¡ Á÷¸éÇÏ¿© °¡°Ý¿¡ ¹Î°¨ÇÑ Áö¿ª¿¡¼ÀÇ µµÀÔÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡, CLIA ±â¼úÀÇ º¹À⼺°ú ¿î¿µÀÚÀÇ Àü¹®ÀûÀÎ ÈÆ·ÃÀÇ Çʿ伺Àº º¸±Þ À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦»óÀÇ Àå¾Ö¹°°ú ¾ö°ÝÇÑ Ç°Áú °ü¸® ¿ä±¸ »çÇ×Àº ½ÃÀå ¿ªÇп¡ ´õ¿í ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖÀ¸¸ç ½ÅÁ¦Ç° äÅðú ½ÃÀå ÁøÀÔ ¼Óµµ¿¡ ¿µÇâÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ:
ÈÇй߱¤ ¸é¿ªÃøÁ¤ ½ÃÀåÀº ºÐ¼®±â¼úÀÇ Çõ½Å, ÀÓ»óÁø´Ü¿¡¼ÀÇ ¿ëµµÀÇ È®´ë, Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ °ü½É Áõ°¡¿¡ ÀÇÇØ Å« ¼ºÀå ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ÀΰøÁö´É ¹× ¸Ó½Å·¯´×°ú °°Àº ÀÚµ¿È ¹× µðÁöÅÐ ±â¼úÀ» CLIA ½Ã½ºÅÛ¿¡ ÅëÇÕÇϸé Áø´Ü Á¤È®µµ¿Í È¿À²¼ºÀ» ³ô¿© ½ÃÀå È®´ëÀÇ »õ·Î¿î ±æÀ» ¿¾î ÁÝ´Ï´Ù. Àü·«Àû ÆÄÆ®³Ê½Ê, R&D ÅõÀÚ, ºñ¿ë È¿À²ÀûÀÎ CLIA ¼Ö·ç¼ÇÀÇ µµÀÔÀº »õ·Î¿î ±âȸ¸¦ Ȱ¿ëÇÏ°í ¿ªµ¿ÀûÀÎ ½ÃÀå ȯ°æ¿¡¼ °æÀï·ÂÀ» À¯ÁöÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
¼¼°èÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
´Ù¾çÇÑ °Ç° °ü¸® ȯ°æ¿¡¼ CLIA ±â¼úÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ºÐ¼® À¯Çü°ú ¿ëµµ´Â?
±â¼úÁøº¸´Â ÈÇй߱¤ ¸é¿ªÃøÁ¤ ½ÃÀå °æÀï ±¸µµ¸¦ ¾î¶»°Ô ¹Ù²Ù°í Àִ°¡?
ÈÇй߱¤ ¸é¿ªÃøÁ¤ ½ÃÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ±â¾÷Àº ¾îµò°¡, ±×¸®°í ½ÃÀåÀÇ °ü·Ã¼ºÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» ÃëÇϰí Àִ°¡?
ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ¼¼°è ½ÃÀå¿¡¼ »õ·Î¿î µ¿Çâ°ú ¹Ì·¡´Â?
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀå ¹üÀ§/ºÐ·ù
½ÃÀåÀÇ Á¤ÀÇ/¹üÀ§/Á¦ÇÑ
Á¦3Àå ½ÃÀå ¸®½ºÅ©¿Í µ¿Çâ Æò°¡
¸®½ºÅ© Æò°¡
COVID-19 À§±â¿Í ÈÇй߱¤ ¸é¿ª ÃøÁ¤¿¡ ¹ÌÄ¡´Â ¿µÇâ
°ú°ÅÀÇ À§±â¿Í ºñ±³ÇÑ COVID-19ÀÇ ¿µÇâ º¥Ä¡¸¶Å©
½ÃÀå ¸ÅÃâ¿¡ ¹ÌÄ¡´Â ¿µÇâ(¹é¸¸ ´Þ·¯)
Æò°¡ : ÁÖ¿ä ±¹°¡º°
Æò°¡ : ÁÖ¿ä ½ÃÀå ºÎ¹®º°
°ø±ÞÀÚ¿¡°Ô ¾×¼Ç Æ÷ÀÎÆ®¿Í Á¦¾È
½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä µ¿Çâ
󹿰ú Á¦Ç° °³¹ß µ¿Çâ
Á¦4Àå ½ÃÀå ¹è°æ
ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå : ÁÖ¿ä ±¹°¡º°
ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ±âȸ Æò°¡(¹é¸¸ ´Þ·¯)
½ÃÀå ½Ã³ª¸®¿À ¿¹Ãø
ÅõÀÚ ½ÇÇö °¡´É¼º ºÐ¼®
¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
½ÃÀå ¿ªÇÐ
Á¦5Àå ÁÖ¿ä ¼º°ø ¿äÀÎ
Á¦Á¶¾÷ü´Â ħÅõÀ²Àº ³·Áö¸¸ ¼ºÀå·üÀÌ ³ôÀº ½ÃÀå¿¡ ÁÖ·Â
ºÎ¹®ÀÇ ³ôÀº ÁõºÐ ±âȸ¿¡ ´ëÇÑ ÅõÀÚ
ÇÇ¾î º¥Ä¡¸¶Å©
Á¦6Àå ¼¼°èÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ¼ö¿ä ºÐ¼®
°ú°Å ½ÃÀå ºÐ¼®, 2019-2023³â
ÇöÀç ¹× Àå·¡ ½ÃÀå ¿¹Ãø, 2024-2032³â
Àü³â´ëºñ ¼ºÀå µ¿Ç⠺м®
Á¦7Àå ¼¼°èÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ¸ÅÃ⠺м®
°ú°Å ½ÃÀå ¸ÅÃâ(¹é¸¸ ´Þ·¯) ºÐ¼®, 2019-2023³â
ÇöÀç ¹× Àå·¡ ½ÃÀå ¸ÅÃâ(¹é¸¸ ´Þ·¯) ¿¹Ãø, 2024-2032³â
Àü³â´ëºñ ¼ºÀå µ¿Ç⠺м®
Àý´ë¾×ÀÇ ±âȸ ºÐ¼®
Á¦8Àå ¼¼°èÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®, Á¦Ç° À¯Çüº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯)ÀÇ ºÐ¼®, Á¦Ç° À¯Çüº°, 2019-2023³â
ÇöÀç ¹× Àå·¡ ½ÃÀå ±Ô¸ð(¹é¸¸ ¹Ì ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, Á¦Ç° À¯Çüº°, 2024-2032³â
±â±â
¼Ò¸ðǰ
¼ÒÇÁÆ®¿þ¾î ¹× ¼ºñ½º
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Á¦Ç° À¯Çüº°
Á¦9Àå ¼¼°èÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®, ¿ëµµº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯)ÀÇ ºÐ¼®, ¿ëµµº°, 2019-2023³â
ÇöÀç ¹× Àå·¡ ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯)ÀÇ ºÐ¼®°ú ¿¹Ãø, ¿ëµµº°, 2024-2032³â
Ä¡·áÁ¦ ¸ð´ÏÅ͸µ
Á¾¾çÇÐ
½ÉÀ庴ÇÐ
³»ºÐºñÇÐ
°¨¿°Áõ
ÀÚ°¡¸é¿ªÁúȯ
±âŸ ¿ëµµ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ¿ëµµº°
Á¦10Àå ¼¼°èÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®, ÃÖÁ¾ ¿ëµµº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯)ÀÇ ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2019-2023³â
ÇöÀç ¹× Àå·¡ ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯)ÀÇ ºÐ¼®°ú ¿¹Ãø, ÃÖÁ¾ ¿ëµµº°, 2024-2032³â
º´¿ø
ÀÓ»ó ½ÇÇè½Ç
Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
±âŸ ÃÖÁ¾ ¿ëµµ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
Á¦11Àå ¼¼°èÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®, Áö¿ªº°
¼Ò°³
°ú°Å ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯)ÀÇ ºÐ¼®, Áö¿ªº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯)¿Í ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°, 2024-2032³â
ºÏ¹Ì
¶óƾ¾Æ¸Þ¸®Ä«
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ªº°
Á¦12Àå ºÏ¹ÌÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
Á¦13Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
Á¦14Àå À¯·´ÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
Á¦15Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÈÇй߱¤ ¸é¿ªÃøÁ¤ ½ÃÀå ºÐ¼®
Á¦16Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
Á¦17Àå ÁÖ¿ä±¹ÀÇ ÈÇй߱¤ ¸é¿ªÃøÁ¤ ½ÃÀå ºÐ¼®
¼Ò°³
½ÃÀå ¸ÅÃâ ºñÀ² ºÐ¼® : ÁÖ¿ä ±¹°¡º°
¼¼°è Vs. ±¹°¡º° ¼ºÀå ºñ±³
¹Ì±¹ÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
ij³ª´ÙÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
¸ß½ÃÄÚÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
ºê¶óÁúÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
µ¶ÀÏÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
ÇÁ¶û½ºÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
ÀÌÅ»¸®¾ÆÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
½ºÆäÀÎÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
¿µ±¹ÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
·¯½Ã¾ÆÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
Áß±¹ÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
ÀϺ»ÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
Çѱ¹ÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
»ç¿ìµð¾Æ¶óºñ¾ÆÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
³²¾ÆÇÁ¸®Ä«ÀÇ ÈÇй߱¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
UAEÀÇ ÈÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤ ½ÃÀå ºÐ¼®
°¡Ä¡ ºñÀ² ºÐ¼® : ½ÃÀå ºÐ·ùº°
±Ý¾×°ú ºÐ¼®°ú ¿¹Ãø : ½ÃÀå ºÐ·ùº°, 2019-2032³â
Á¦Ç° À¯Çüº°
ÃÖÁ¾ ¿ëµµº°
¿ëµµº°
±¹³» °æÀï ±¸µµ¿Í ±â¾÷ ÁýÁßµµ
Á¦18Àå ½ÃÀå ±¸Á¶ ºÐ¼®
½ÃÀå ºÐ¼® : ±â¾÷ Tierº°
½ÃÀå ÁýÁß
ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
½ÃÀåÇöÀçºÐ¼®
Á¦19Àå °æÀï ºÐ¼®
°æÀï ´ë½Ãº¸µå
°æÀï º¥Ä¡¸¶Å·
°æÀïÀÇ »ó¼¼ Á¤º¸
DiaSorin SpA
Abbott Laboratories
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Immunodiagnostic Systems
Siemens Healthineers
Beckman Coulter Inc.
F. Hoffmann-La Roche AG
Inova Diagnostics, Inc.
Maccura Biotechnology Co., Ltd.
Ortho Clinical Diagnostics
Á¦20Àå »ç¿ëµÈ ÀüÁ¦Á¶°Ç°ú ¾à¾î
Á¦21Àå Á¶»ç ¹æ¹ý
JHS
Persistence Market Research has recently released a comprehensive report on the global Chemiluminescence Immunoassay (CLIA) market. The report provides an in-depth evaluation of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market structure.
Key Insights:
Chemiluminescence Immunoassay Market Size (2024E): USD 9.5 Million
Projected Market Value (2032F): USD 21.6 Million
Global Market Growth Rate (CAGR 2024 to 2032): 9.5%
Chemiluminescence Immunoassay Market - Report Scope:
Chemiluminescence Immunoassays are critical tools in diagnostic laboratories for detecting and quantifying various biomarkers, including hormones, proteins, and other molecules. These assays utilize light emission triggered by chemical reactions to provide highly sensitive and specific analytical results. The market for CLIA caters to hospitals, diagnostic laboratories, research institutions, and pharmaceutical companies, offering a range of products, including reagents, instruments, and consumables.
Market growth is driven by the increasing prevalence of chronic diseases, advancements in assay technologies, and rising demand for accurate diagnostic tools. The adoption of CLIA technology is further supported by its ability to deliver high-throughput results with minimal sample volumes, making it an essential component in modern diagnostics.
Market Growth Drivers:
The global Chemiluminescence Immunoassay market is propelled by several key factors, including the growing incidence of chronic and infectious diseases, which necessitates advanced diagnostic methods for early detection and management. The increasing adoption of personalized medicine and the rising demand for efficient and reliable diagnostic solutions further drive market expansion. Technological advancements, such as the development of high-sensitivity and high-throughput CLIA systems, are enhancing diagnostic capabilities and contributing to market growth. Moreover, the expansion of diagnostic laboratories and healthcare facilities in emerging markets creates new opportunities for CLIA providers.
Market Restraints:
Despite promising growth prospects, the Chemiluminescence Immunoassay market faces challenges related to high costs associated with CLIA systems and reagents, which may limit adoption in price-sensitive regions. Additionally, the complexity of CLIA technology and the need for specialized training for operators can pose barriers to widespread implementation. Regulatory hurdles and stringent quality control requirements further impact market dynamics, potentially affecting the speed of new product introductions and market entry.
Market Opportunities:
The Chemiluminescence Immunoassay market presents significant growth opportunities driven by innovations in assay technologies, expanding applications in clinical diagnostics, and the increasing focus on early disease detection. The integration of automation and digital technologies, such as artificial intelligence and machine learning, into CLIA systems enhances diagnostic accuracy and efficiency, creating new avenues for market expansion. Strategic partnerships, investments in research and development, and the introduction of cost-effective CLIA solutions are essential for capitalizing on emerging opportunities and maintaining a competitive edge in the dynamic market landscape.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the Chemiluminescence Immunoassay market globally?
Which assay types and applications are driving the adoption of CLIA technologies across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the Chemiluminescence Immunoassay market?
Who are the key players contributing to the Chemiluminescence Immunoassay market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global Chemiluminescence Immunoassay market?
Competitive Intelligence and Business Strategy:
Leading players in the global Chemiluminescence Immunoassay market, including Abbott Laboratories, Siemens Healthineers, and Roche Diagnostics, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced CLIA systems and reagents, catering to diverse diagnostic needs and clinical applications. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Emphasis on clinical research, evidence-based practice, and user training enhances market growth and improves diagnostic outcomes in the evolving Chemiluminescence Immunoassay landscape.
Key Companies Profiled:
Abbott Laboratories
Siemens Healthineers
Roche Diagnostics
Beckman Coulter, Inc.
Ortho Clinical Diagnostics
Bio-Rad Laboratories
Fujirebio Diagnostics
Diagnostic Systems Laboratories, Inc.
Thermo Fisher Scientific Inc.
Diasorin S.p.A.
Market Segments Covered in Chemiluminescence Immunoassay Industry Analysis
By Product Type
Instruments
Consumables
Software & Services
By Application
Therapeutic Drug Monitoring
Oncology
Cardiology
Endocrinology
Infectious Disease
Autoimmune Disease
Other Applications
By End-use
Hospitals
Clinical Laboratories
Pharmaceutical & Biotechnology Companies
Other End-uses
By Region
North America
Europe
APAC
Latin America
MEA
Table of Contents
1. Executive Summary
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Chemiluminescence Immunoassay
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Mn)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background
4.1. Chemiluminescence Immunoassay Market, by Key Countries
4.2. Chemiluminescence Immunoassay Market Opportunity Assessment (US$ Mn)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Growth in Automation, By Country
4.5.3. Patch Management Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Patch Management Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers' Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Chemiluminescence Immunoassay Market Demand Analysis 2019-2023 and Forecast, 2024-2032
6.1. Historical Market Analysis, 2019-2023
6.2. Current and Future Market Projections, 2024-2032
6.3. Y-o-Y Growth Trend Analysis
7. Global Chemiluminescence Immunoassay Market Value Analysis 2019-2023 and Forecast, 2024-2032
7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032, By Product Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2024-2032
8.3.1. Instruments
8.3.1.1. Automated
8.3.1.2. Semi-automated
8.3.2. Consumables
8.3.3. Software & Services
8.4. Market Attractiveness Analysis By Product Type
9. Global Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032, By Application
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Application, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2032
9.3.1. Therapeutic Drug Monitoring
9.3.2. Oncology
9.3.3. Cardiology
9.3.4. Endocrinology
9.3.5. Infectious Disease
9.3.6. Autoimmune Disease
9.3.7. Other Applications
9.4. Market Attractiveness Analysis By Application
10. Global Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032, By End-use
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By End-use, 2019-2023
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End-use, 2024-2032
10.3.1. Hospitals
10.3.2. Clinical Laboratories
10.3.3. Pharmaceutical & Biotechnology Companies
10.3.4. Other End-uses
10.4. Market Attractiveness Analysis By End-use
11. Global Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
11.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2024-2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Asia Pacific
11.3.5. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
12.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
12.4.1. By Country
12.4.1.1. U.S.
12.4.1.2. Canada
12.4.1.3. Rest of North America
12.4.2. By Product Type
12.4.3. By End-use
12.4.4. By Application
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Product Type
12.5.3. By End-use
12.5.4. By Application
13. Latin America Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
13.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
13.4.1. By Country
13.4.1.1. Brazil
13.4.1.2. Mexico
13.4.1.3. Rest of Latin America
13.4.2. By Product Type
13.4.3. By End-use
13.4.4. By Application
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Product Type
13.5.3. By End-use
13.5.4. By Application
14. Europe Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
14.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
14.4.1. By Country
14.4.1.1. Germany
14.4.1.2. France
14.4.1.3. U.K.
14.4.1.4. Italy
14.4.1.5. Spain
14.4.1.6. Russia
14.4.1.7. Rest of Europe
14.4.2. By Product Type
14.4.3. By End-use
14.4.4. By Application
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Product Type
14.5.3. By End-use
14.5.4. By Application
15. Asia Pacific Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
15.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
15.4.1. By Country
15.4.1.1. China
15.4.1.2. Japan
15.4.1.3. South Korea
15.4.1.4. Rest of Asia Pacific
15.4.2. By Product Type
15.4.3. By End-use
15.4.4. By Application
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Product Type
15.5.3. By End-use
15.5.4. By Application
16. Middle East and Africa Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
16.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
16.4.1. By Country
16.4.1.1. Saudi Arabia
16.4.1.2. South Africa
16.4.1.3. UAE
16.4.1.4. Rest of Middle East and Africa
16.4.2. By Product Type
16.4.3. By End-use
16.4.4. By Application
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Product Type
16.5.3. By End-use
16.5.4. By Application
17. Key Countries Chemiluminescence Immunoassay Market Analysis 2019-2023 and Forecast 2024-2032
17.1. Introduction
17.1.1. Market Value Proportion Analysis, By Key Countries
17.1.2. Global Vs. Country Growth Comparison
17.2. US Chemiluminescence Immunoassay Market Analysis
17.2.1. Value Proportion Analysis by Market Taxonomy
17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.2.2.1. By Product Type
17.2.2.2. By End-use
17.2.2.3. By Application
17.3. Canada Chemiluminescence Immunoassay Market Analysis
17.3.1. Value Proportion Analysis by Market Taxonomy
17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.3.2.1. By Product Type
17.3.2.2. By End-use
17.3.2.3. By Application
17.4. Mexico Chemiluminescence Immunoassay Market Analysis
17.4.1. Value Proportion Analysis by Market Taxonomy
17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.4.2.1. By Product Type
17.4.2.2. By End-use
17.4.2.3. By Application
17.5. Brazil Chemiluminescence Immunoassay Market Analysis
17.5.1. Value Proportion Analysis by Market Taxonomy
17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.5.2.1. By Product Type
17.5.2.2. By End-use
17.5.2.3. By Application
17.6. Germany Chemiluminescence Immunoassay Market Analysis
17.6.1. Value Proportion Analysis by Market Taxonomy
17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.6.2.1. By Product Type
17.6.2.2. By End-use
17.6.2.3. By Application
17.7. France Chemiluminescence Immunoassay Market Analysis
17.7.1. Value Proportion Analysis by Market Taxonomy
17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.7.2.1. By Product Type
17.7.2.2. By End-use
17.7.2.3. By Application
17.8. Italy Chemiluminescence Immunoassay Market Analysis
17.8.1. Value Proportion Analysis by Market Taxonomy
17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.8.2.1. By Product Type
17.8.2.2. By End-use
17.8.2.3. By Application
17.9. Spain Chemiluminescence Immunoassay Market Analysis
17.9.1. Value Proportion Analysis by Market Taxonomy
17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.9.2.1. By Product Type
17.9.2.2. By End-use
17.9.2.3. By Application
17.10. UK Chemiluminescence Immunoassay Market Analysis
17.10.1. Value Proportion Analysis by Market Taxonomy
17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.10.2.1. By Product Type
17.10.2.2. By End-use
17.10.2.3. By Application
17.11. Russia Chemiluminescence Immunoassay Market Analysis
17.11.1. Value Proportion Analysis by Market Taxonomy
17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.11.2.1. By Product Type
17.11.2.2. By End-use
17.11.2.3. By Application
17.12. China Chemiluminescence Immunoassay Market Analysis
17.12.1. Value Proportion Analysis by Market Taxonomy
17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.12.2.1. By Product Type
17.12.2.2. By End-use
17.12.2.3. By Application
17.13. Japan Chemiluminescence Immunoassay Market Analysis
17.13.1. Value Proportion Analysis by Market Taxonomy
17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.13.2.1. By Product Type
17.13.2.2. By End-use
17.13.2.3. By Application
17.14. South Korea Chemiluminescence Immunoassay Market Analysis
17.14.1. Value Proportion Analysis by Market Taxonomy
17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.14.2.1. By Product Type
17.14.2.2. By End-use
17.14.2.3. By Application
17.15. Saudi Arabia Chemiluminescence Immunoassay Market Analysis
17.15.1. Value Proportion Analysis by Market Taxonomy
17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.15.2.1. By Product Type
17.15.2.2. By End-use
17.15.2.3. By Application
17.16. South Africa Chemiluminescence Immunoassay Market Analysis
17.16.1. Value Proportion Analysis by Market Taxonomy
17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.16.2.1. By Product Type
17.16.2.2. By End-use
17.16.2.3. By Application
17.17. UAE Chemiluminescence Immunoassay Market Analysis
17.17.1. Value Proportion Analysis by Market Taxonomy
17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2019-2032
17.17.2.1. By Product Type
17.17.2.2. By End-use
17.17.2.3. By Application
17.17.3. Competition Landscape and Player Concentration in the Country
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Concentration
18.3. Market Share Analysis of Top Players
18.4. Market Presence Analysis
18.4.1. By Regional footprint of Players
18.4.2. Product footprint by Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. DiaSorin S.p.A.
19.3.1.1. Overview
19.3.1.2. Product Portfolio
19.3.1.3. Sales Footprint
19.3.1.4. Strategy Overview
19.3.2. Abbott Laboratories
19.3.2.1. Overview
19.3.2.2. Product Portfolio
19.3.2.3. Sales Footprint
19.3.2.4. Strategy Overview
19.3.3. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
19.3.3.1. Overview
19.3.3.2. Product Portfolio
19.3.3.3. Sales Footprint
19.3.3.4. Strategy Overview
19.3.4. Immunodiagnostic Systems
19.3.4.1. Overview
19.3.4.2. Product Portfolio
19.3.4.3. Sales Footprint
19.3.4.4. Strategy Overview
19.3.5. Siemens Healthineers
19.3.5.1. Overview
19.3.5.2. Product Portfolio
19.3.5.3. Sales Footprint
19.3.5.4. Strategy Overview
19.3.6. Beckman Coulter Inc.
19.3.6.1. Overview
19.3.6.2. Product Portfolio
19.3.6.3. Sales Footprint
19.3.6.4. Strategy Overview
19.3.7. F. Hoffmann-La Roche AG
19.3.7.1. Overview
19.3.7.2. Product Portfolio
19.3.7.3. Sales Footprint
19.3.7.4. Strategy Overview
19.3.8. Inova Diagnostics, Inc.
19.3.8.1. Overview
19.3.8.2. Product Portfolio
19.3.8.3. Sales Footprint
19.3.8.4. Strategy Overview
19.3.9. Maccura Biotechnology Co., Ltd.
19.3.9.1. Overview
19.3.9.2. Product Portfolio
19.3.9.3. Sales Footprint
19.3.9.4. Strategy Overview
19.3.10. Ortho Clinical Diagnostics
19.3.10.1. Overview
19.3.10.2. Product Portfolio
19.3.10.3. Sales Footprint
19.3.10.4. Strategy Overview
20. Assumptions and Acronyms Used
21. Research Methodology